All Insurance Policy Changes (Page 1117)

Continuing from page 1116. Showing older policy changes tracked across all payers. Use the filters in the related-hubs section below to narrow by provider, state, or specialty.

Medium impact
MA05.024i, Lower Limb Prostheses
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.024i for Lower Limb Prostheses has been reissued and will be effective April 2, 2025. This is a policy reissue that may contain updated coverage criteria, billing requirements, or documentation standards for lower limb prosthetic devices and services.
Medium impact
MA05.002f, Hospital Beds and Accessories
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.002f for Hospital Beds and Accessories has been reissued and will take effect on April 2, 2025. This is a policy update that may affect coverage criteria, billing requirements, or documentation standards for hospital beds and related equipment.
Medium impact
MA05.045e, Compression Garments
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.045e for compression garments has been reissued with updates effective April 2, 2025. This is a very recent policy change that may affect coverage criteria, billing requirements, or documentation standards for compression garments.
Medium impact
MA05.042d, Pulse Oximetry Device in the Home Setting
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.042d regarding pulse oximetry devices in home settings has been reissued with an effective date of April 2, 2025. This is a policy update that may affect coverage criteria, billing requirements, or documentation standards for home pulse oximetry equipment.
Medium impact
MA04.002, Extraction of Bony Impacted Teeth and Exposure of Impacted Teeth
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA04.002 for extraction of bony impacted teeth and exposure of impacted teeth has been reissued with updates effective April 2, 2025. This is a fresh policy update that may affect coverage criteria or billing requirements for dental surgical procedures under Medicare Advantage plans.
Medium impact
MA11.033c, Solid Organ Transplantation and Procurement Cost of Organs and Tissues
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA11.033c for Solid Organ Transplantation and Procurement Cost of Organs and Tissues has been reissued with an effective date of April 2, 2025. This is a policy reissue that may contain updated coverage criteria, billing requirements, or procedural changes for organ transplantation services.
Medium impact
MA07.002i, Ultraviolet Light Therapy for the Treatment of Dermatological Conditions
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA07.002i regarding ultraviolet light therapy for dermatological conditions has been reissued and will become effective April 2, 2025. This is a policy update that may affect coverage criteria, billing requirements, or documentation standards for UV light therapy procedures.
Medium impact
MA05.054j, Urological Supplies
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.054j for Urological Supplies has been reissued and will become effective April 2, 2025. This is a policy update that may affect coverage, billing, or documentation requirements for urological supplies and related procedures.
Medium impact
MA11.022a, Cryosurgical Ablation of the Prostate Gland
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA11.022a regarding cryosurgical ablation of the prostate gland has been reissued and will take effect April 2, 2025. This is a policy update that may affect coverage, billing, or documentation requirements for prostate cryosurgery procedures.
Medium impact
MA05.018d, Non-Spinal Osteogenic Stimulators (Electrical and Ultrasonic)
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.018d for Non-Spinal Osteogenic Stimulators (Electrical and Ultrasonic) has been reissued and will take effect April 2, 2025. This policy update affects coverage and billing requirements for bone growth stimulators used outside the spine.
Medium impact
MA08.015d, Alemtuzumab (Lemtrada®)
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA08.015d for Alemtuzumab (Lemtrada®) has been reissued with updates effective April 2, 2025. This is a pharmacy-related policy change affecting coverage or administration requirements for this multiple sclerosis medication.
Medium impact
MA08.029c, Natalizumab (Tysabri®) and Related Biosimilars
Independence Blue Cross·Effective Apr 2, 2025
The Medicare Advantage policy MA08.029c for Natalizumab (Tysabri®) and Related Biosimilars has been reissued and will take effect April 2, 2025. This is a pharmacy policy update that may affect coverage or authorization requirements for this multiple sclerosis medication.
Medium impact
MA08.003h, Enteral Nutritional Therapy
Independence Blue Cross·Effective Apr 4, 2025
Medicare Advantage policy MA08.003h for Enteral Nutritional Therapy has been reissued with updates effective April 4, 2025. This is a fresh policy update that may contain changes to coverage criteria, billing requirements, or documentation standards for enteral nutrition services.
Medium impact
MA07.010c, Biofeedback Therapy
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA07.010c for Biofeedback Therapy has been reissued and will be effective April 2, 2025. This is a policy update that may affect coverage criteria, billing requirements, or documentation standards for biofeedback therapy services.
Medium impact
MA08.156c, Teclistamab-cqyv (Tecvayli®)
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA08.156c for Teclistamab-cqyv (Tecvayli®) has been reissued with updates effective April 2, 2025. This is a pharmacy policy change affecting coverage or administration requirements for this specialty oncology medication used to treat multiple myeloma.
Medium impact
MA05.027d, Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) for Treating Life-threatening Ventricular Tachyarrhythmia
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.027d regarding Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) for treating life-threatening ventricular tachyarrhythmia has been reissued with an effective date of April 2, 2025. This is a coding-related policy update that may affect billing procedures for S-ICD devices and related services.
Medium impact
MA10.001c, Pulmonary Rehabilitation
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA10.001c for Pulmonary Rehabilitation has been reissued and will be effective April 2, 2025. This is a policy update that may contain changes to coverage criteria, billing requirements, or documentation standards for pulmonary rehabilitation services.
Medium impact
MA11.107f, Steroid-Eluting Sinus Stents and Implants
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA11.107f regarding Steroid-Eluting Sinus Stents and Implants has been reissued with updates effective April 2, 2025. This policy change affects coverage or billing requirements for sinus stent procedures under Medicare Advantage plans.
Medium impact
MA11.056h, Percutaneous Transluminal Angioplasty (PTA) Concurrent with or without Stenting and Extracranial- Intracranial (EC-IC) Arterial Bypass Surgery
Independence Blue Cross·Effective Apr 2, 2025
This is a reissued policy (MA11.056h) effective April 2, 2025 governing coverage and billing for Percutaneous Transluminal Angioplasty (PTA) with or without stenting performed concurrently with Extracranial-Intracranial (EC-IC) arterial bypass surgery. The billing team must review the full policy text to identify specific coverage criteria, prior authorization requirements, and applicable billing codes for these neurovascular procedures under Medicare Advantage plans.
High impact
MA11.027e, Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Edge-to-Edge Repair (TEER) of the Mitral Valve
Independence Blue Cross·Effective Apr 2, 2025
Policy MA11.027e has been reissued effective April 2, 2025, addressing coverage and billing requirements for Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Edge-to-Edge Repair (TEER) of the mitral valve procedures. The billing team must review the full policy text to identify specific code changes, prior authorization requirements, or documentation updates that may affect claim submission and reimbursement for these cardiac interventional procedures.
Medium impact
MA10.002f, Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA10.002f for Cardiac Rehabilitation and Intensive Cardiac Rehabilitation Programs has been reissued with updates effective April 2, 2025. This is a fresh policy update that may contain changes to coverage criteria, billing requirements, or authorization processes for cardiac rehab services.
Medium impact
MA11.100f, Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis
Independence Blue Cross·Effective Apr 2, 2025
This is a reissued policy (effective 04/02/2025) governing balloon catheter dilation of sinus ostia for treatment of chronic rhinosinusitis or recurrent acute rhinosinusitis. The billing team must review the full policy text to identify any changes from the previous version and update coverage, prior authorization, and billing requirements accordingly for Medicare Advantage plans.
Medium impact
MA05.046j, Wheelchair Options and Accessories
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.046j for Wheelchair Options and Accessories has been reissued with updates effective April 2, 2025. This policy governs coverage criteria and billing requirements for wheelchairs and related accessories under Medicare Advantage plans.
Medium impact
MA05.067f, Leadless Pacemakers
Independence Blue Cross·Effective Apr 2, 2025
Medicare Advantage policy MA05.067f for leadless pacemakers has been reissued and will be effective April 2, 2025. This is a policy update that may affect coverage criteria, billing requirements, or documentation standards for leadless pacemaker procedures under Medicare Advantage plans.
Medium impact
MA05.005g, Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)
Independence Blue Cross·Effective Apr 2, 2025
MA05.005g policy regarding Automatic External Cardioverter Defibrillators (wearable and nonwearable devices) has been reissued effective April 2, 2025. This recent policy update may contain changes to coverage criteria, prior authorization requirements, or billing guidelines for AED devices under Medicare Advantage plans. The billing team must review the full policy details to identify specific changes from the previous version.

Browse by payer Browse by state Browse by specialty Browse by billing code Browse & filter all changes

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Archive by year

2023 2024 2025 2026

MA05.024i, Lower Limb Prostheses

MA05.002f, Hospital Beds and Accessories

MA05.045e, Compression Garments

MA05.042d, Pulse Oximetry Device in the Home Setting

MA04.002, Extraction of Bony Impacted Teeth and Exposure of Impacted Teeth

MA11.033c, Solid Organ Transplantation and Procurement Cost of Organs and Tissues

MA07.002i, Ultraviolet Light Therapy for the Treatment of Dermatological Conditions

MA05.054j, Urological Supplies

MA11.022a, Cryosurgical Ablation of the Prostate Gland

MA05.018d, Non-Spinal Osteogenic Stimulators (Electrical and Ultrasonic)

MA08.015d, Alemtuzumab (Lemtrada®)

MA08.029c, Natalizumab (Tysabri®) and Related Biosimilars

MA08.003h, Enteral Nutritional Therapy

MA07.010c, Biofeedback Therapy

MA08.156c, Teclistamab-cqyv (Tecvayli®)

MA05.027d, Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) for Treating Life-threatening Ventricular Tachyarrhythmia

MA10.001c, Pulmonary Rehabilitation

MA11.107f, Steroid-Eluting Sinus Stents and Implants

MA11.056h, Percutaneous Transluminal Angioplasty (PTA) Concurrent with or without Stenting and Extracranial- Intracranial (EC-IC) Arterial Bypass Surgery

MA11.027e, Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Edge-to-Edge Repair (TEER) of the Mitral Valve

MA10.002f, Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs

MA11.100f, Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis or Recurrent Acute Rhinosinusitis

MA05.046j, Wheelchair Options and Accessories

MA05.067f, Leadless Pacemakers

MA05.005g, Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)